Husseinzadeh Nader, Husseinzadeh Holleh D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Cincinnati, 231 Albert Sabin Way. Cincinnati, Ohio 45267, USA.
Taussig Cancer Center, Cleveland Clinic Foundation. 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.
World J Oncol. 2013 Feb;4(1):1-7. doi: 10.4021/wjon616w. Epub 2013 Mar 6.
The aim of this review is to present an overview of available methods for preservation of ovarian function and fertility in female cancer patients who desire to maintain their child-bearing capacity for future pregnancies. A Medline search was conducted. Published articles from American and European studies from 1976 to present were reviewed. The effect of cancer treatment on the ovary, as well as different methods of fertility preservation and their reproductive outcomes are presented. Pregnancy rates vary according to the type of primary malignancy, stage of disease, method of fertility preservation (for example, hormonal therapy, cryopreservation, fertility-sparing surgery), and other confounding factors such as the patient's age, reproductive capacity, status of partnership, and genetic disposition. The highest rates of successful pregnancy were observed with embryo cryopreservation. Today, higher cure rates and longer survival are a result of earlier cancer diagnosis and treatment. In conjunction with the advances in assisted reproduction, the preservation of ovarian function and fertility is a major part of multidisciplinary care that should be offered to any young female patient with cancer. Fertility preservation in young cancer patients raises a number of ethical issues particularly regarding standard versus experimental therapies, and long-term financial cost.
本综述的目的是概述为希望保留未来生育能力以便日后怀孕的女性癌症患者保留卵巢功能和生育能力的现有方法。进行了医学文献数据库(Medline)检索。对1976年至今美国和欧洲研究发表的文章进行了综述。阐述了癌症治疗对卵巢的影响,以及不同的生育力保留方法及其生殖结局。妊娠率因原发性恶性肿瘤的类型、疾病分期、生育力保留方法(例如,激素治疗、冷冻保存、保留生育功能手术)以及其他混杂因素(如患者年龄、生殖能力、伴侣状况和遗传倾向)而异。胚胎冷冻保存的成功妊娠率最高。如今,更高的治愈率和更长的生存期得益于癌症的早期诊断和治疗。随着辅助生殖技术的进步,保留卵巢功能和生育能力是多学科护理的重要组成部分,应提供给任何年轻的女性癌症患者。年轻癌症患者的生育力保留引发了一些伦理问题,尤其是关于标准疗法与实验性疗法以及长期财务成本的问题。